Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | An update on erdafitinib for metastatic/uresectable FGFR alteration urothelial carcinoma

Arlene Siefker-Radtke • 6 Mar 2019
GU Cancers 2019
Bladder Cancer Genitourinary Cancer Erdafitinib
THOR

The Phase III THOR study (NCT03390504) is investigating erdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients with metastatic or surgically unresectable urothelial carcinoma and selected FGFR gene alterations. We spoke to Arlene Siefker-Radtke, MD of the University of Texas MD Anderson Cancer Center, Houston, TX, about this study and its progress. This interview took place at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Arlene Siefker-Radtke

1:47
The future role of erdafitinib in advanced urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:34
RAGNAR: histology-agnostic trial of erdafitinib in FGFR3-mutant tumors
Arlene Siefker-Radtke • 4 Jun 2023
2:34
NORSE: erdafitinib and cetrelimab in urothelial carcinoma
Arlene Siefker-Radtke • 4 Jun 2023
1:15
What role will erdafitinib play in treating metastatic urothelial carcinoma?
Arlene Siefker-Radtke • 4 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals